References
- Ambrose, P. G., Hammel, J. P., Bhavnavi, S. M., Ellis-Grosse, E. J., Drusano, G. I. (2012), “Frequentist and Bayesian Pharmacometric-based Approaches to Facilitate Critically Needed New Antibiotic Development Overcoming Lies, Damn Lies, and Statistics,” Antimicrobial Agents and Chemotherapy, 56, 1466–1470.
- Craig, W. A. (1998), “Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men,” Clinical Infectious Disease, 26, 1–10.
- Dudley, M. N., Ambrose, P. G., Bhavnani, S. M., Craig, W. A., Ferraro, M. J., and Jones, R. N., Antimicrobial Susceptibility Testing Subcommittee of the Clinical, Laboratory Standards Institute (2013), “Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretative Criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam,” Clinical Infectious Disease, 56, 1301–1309.
- Evans, S. R., and Follmann, D. (2015), “Comment: Fundamentals and Innovation in Antibiotic Trials,” Statistics in Biopharmaceutical Research, 7, 331–336.
- European Committee on Antimicrobial Susceptibility Testing, (2017), “Setting Breakpoint for New Antimicrobial Agents,” available at http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/EUCAST_SOPs/EUCAST_SOP_1.2_Setting_breakpoints_new_agents_20161121.pdf.
- Follmann, D., and Brittain, E. (2017), “Half Blind Superiority Tests for Clinical Trials of Anti-infective Drugs,” manuscript in preparation.
- Follmann, D., Brittain, E., and Powers, J. H. (2013), “Discordant Minimum Inhibitory Concentration Analysis: A New Path to Licensure for Anti-infective Drugs,” Clinical Trials, 10, 876–885.
- Food and Drug Administration (FDA) (2013), “Guidance for Industry Antibacterial Therapies for Patients With Unmet Medical Need for the Treatment of Serious Bacterial Diseases,” available at https://www.fda.gov/downloads/Drugs/Guidances/UCM359184.pdf.
- ——— (2016), “Guidance for Industry: Non-Inferiority Clinical Trials to Establish Effectiveness,” available at https://www.fda.gov/downloads/Drugs/Guidances/UCM202140.pdf.
- Hauck, W. W. (1983), “A Note on Confidence Bands for the Logistic Response Curve,” The American Statistician, 37, 158–160.
- Huque, M. F., Valappil, T., and Soon, G. (2014), “Hierarchical Nested Trial Design (HNTD) for Demonstrating Treatment Efficacy of New Antibacterial Drugs in Patient Populations with Emerging Bacterial Resistance,” Statistics in Medicine, 33, 4321–4336.
- MacGowan, A. P., and Wise, R. (2001), “Establishing MIC Breakpoints and the Interpretation of in Vitro Susceptibility Tests,” Journal of Antimicrobial Chemotherapy, 48, 17–28.
- Price, D. L., Rubin, D. R., and Valappil, T. (2015), “Antimicrobial Products: Statistical Challenges and Opportunities,” Statistics in Biopharmaceutical Research, 7, 325–330.